Aligos Therapeutics (NASDAQ:ALGS) Sees Large Volume Increase

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw unusually-high trading volume on Tuesday . Approximately 13,175 shares changed hands during mid-day trading, a decline of 53% from the previous session’s volume of 28,180 shares.The stock last traded at $8.31 and had previously closed at $8.10.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a report on Friday.

Aligos Therapeutics Stock Performance

The stock has a market cap of $624.88 million, a price-to-earnings ratio of -6.33 and a beta of 2.18. The stock’s 50-day simple moving average is $13.09 and its two-hundred day simple moving average is $16.08.

Aligos Therapeutics (NASDAQ:ALGS) last released its earnings results on Tuesday, August 6th. The company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. The firm had revenue of $1.06 million during the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same period in the prior year, the firm earned ($10.75) EPS. As a group, research analysts predict that Aligos Therapeutics, Inc. will post -8.15 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Armistice Capital LLC lifted its position in Aligos Therapeutics by 5.3% during the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after acquiring an additional 363,000 shares during the last quarter. Altitude Crest Partners Inc. acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at about $1,889,000. Opaleye Management Inc. raised its position in shares of Aligos Therapeutics by 25.7% during the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock valued at $1,597,000 after buying an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC raised its position in shares of Aligos Therapeutics by 26.1% during the second quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after buying an additional 171,490 shares during the last quarter. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).